Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

NCT04535960 · Unknown status

Last updated 2026-05-28

This clinical trial is testing how a combination of two diabetes medications affects fluid balance in people with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 36 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2019-01 · est. completion 2023-10

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT04535960 ↗

Description as written by the study sponsor.

This study aims to provide essential mechanistic insights into natriuretic and hemodynamic effects of SGLT2i and GLP-1RA agents in T2D patients. Ultimately, by obtaining physiological data in T2D patients without HF, our aims are to gain insight into how the use of this combined therapy may be used in T2D with HF in future work.

Treatments tested

Empagliflozin 25 MG + Liraglutide 1.8 MG also known as Generic names are above, listed Drug

Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
Liraglutide 1.8 MG + Empagliflozin 25 MG also known as Generic names are above, listed Drug

Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.

Main thing measured	Proximal tubular natriuresis
Sponsor	University Health Network, Toronto
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04535960 ↗